<DOC>
	<DOCNO>NCT02403596</DOCNO>
	<brief_summary>This study evaluate efficacy tranexamic acid versus placebo perioperative blood loss use two dosage regimen ( standard extend ) surgery total hip arthroplasty patient receive novel fast-acting oral anticoagulant rivaroxaban prophylaxis thrombosis .</brief_summary>
	<brief_title>Blood-sparing During Hip Prosthesis Surgery With ExacylÂ® Patients Treated With Rivaroxaban</brief_title>
	<detailed_description>In 2011 , 140 000 total hip replacement perform bleed remain one major complication responsible significant morbidity . This study evaluate new treatment prevent bleed due surgery . Indeed , tranexamic acid ( Exacyl ) use two mode administration ( standard extend ) versus placebo combine Rivaroxaban treatment dose 10 mg / day 35 day . Patients randomize ( exacyl standard v exacyl extend vs. placebo ) follow 3 month .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Over 18 year age Scheduled undergo elective nontraumatic primary cementless THA Having give write informed consent participate trial Covered Social Security Rapidly destructive arthrosis hip History prior surgery operative hip Contraindications use tranexamic acid : Ischaemic artery disease ( angina pectoris , myocardial infarction , acute coronary syndrome stroke ) History venous thromboembolism Severe renal impairment , i.e . clearance &lt; 30mL/mn Epilepsy history convulsion Contraindications use rivaroxaban Severe renal failure ( clearance &lt; 30ml / min ) Cirrhotic patient Child Pugh B Pregnancy breastfeed Cognitive disorder precludes give informed consent Refusal participate trial Allergy either trial treatment Ongoing prophylaxis thrombosis use agent rivaroxaban Ongoing platelet aggregation inhibitor dose exceed 125 mg daily</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hip replacement</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>exacyl</keyword>
	<keyword>blood loss</keyword>
</DOC>